PORCN and cancer: Currently, five small‐molecule PORCN inhibitors are evaluated in clinical trials for cancer treatment (ClinicalTrials.gov, NCT01351103, NCT02278133, NCT02521844, NCT03447470, NCT02675946, NCT03901950, and NCT03507998).